The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol

Preclinical and clinical research shows that the cannabinoid brain receptor type 1 (CB1) modulates alcohol- and nicotine-related behaviors. Throughout the nicotine-induced relapse to alcohol, the rats were pre-treated for 10 days with the CB1 cannabinoid receptor antagonist rimonabant (0, 0.03, 0.3...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: José Antonio López-Moreno, Gustavo González-Cuevas, Miguel Navarro
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Elsevier 2007-02-01
Saila:Neurobiology of Disease
Gaiak:
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S0969996106002385